Mitochondria and ubiquitin-proteasomal system interplay: Relevance to Parkinson's disease

Free Radical Biology and Medicine

Volumn 45, Issue 6, 2008, Pages 820-825

  Domingues, Ana F ^a   Arduíno, Daniela M ^a   Esteves, A Raquel ^a   Swerdlow, Russell H ^b   Oliveira, Catarina R ^a,c   Cardoso, Sandra M ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Mitochondria; Mitochondrial DNA depleted cells; MPP+; Parkinson's disease; Reactive oxygen species; Ubiquitin proteasome system

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CARBONYL DERIVATIVE; CHYMOTRYPSIN; LACTACYSTIN; MITOCHONDRIAL DNA; PROTEASOME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUITIN;

ARTICLE; BRAIN MITOCHONDRION; CELL STRESS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME INHIBITION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; RESPIRATORY CHAIN; UBIQUITINATION;

CELL LINE, TUMOR; HUMANS; HYDROLYSIS; MITOCHONDRIA; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; REACTIVE OXYGEN SPECIES; SPECTROMETRY, FLUORESCENCE; UBIQUITIN;

EID: 54949100005     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2008.06.007     Document Type: Article

References (38)

1. Cardoso S.M., Moreira P.I., Agostinho P., Pereira C., and Oliveira C.R. Neurodegenerative pathways in Parkinson's disease: therapeutic strategies. Curr. Drug Targets. CNS Neurol. Disord. 4 (2005) 405-419
2. Horowitz J.M., Vernace V.A., Myers J., Stachowiak M.K., Hanlon D.W., Fraley G.S., and Torres G. Immunodetection of Parkin protein in vertebrate and invertebrate brains: a comparative study using specific antibodies. J. Chem. Neuroanat. 21 (2001) 75-93
3. Wang C., Tan J.M., Ho M.W., Zaiden N., Wong S.H., Chew C.L., Eng P.W., Lim T.M., Dawson T.M., and Lim K.L. Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem. 93 (2005) 422-431
4. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., and Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246 (1989) 670-673
5. Lowe J., and Mayer R.J. Ubiquitin, cell stress and diseases of the nervous system. Neuropathol. Appl. Neurobiol. 16 (1990) 281-291
6. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
7. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T., and Wada K. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23 (1999) 47-51
8. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury Jr. P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002) 209-218
9. Graham D.G., Tiffany S.M., Bell Jr. W.R., and Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14 (1978) 644-653
10. Maker H.S., Weiss C., Weissbarth S., Silides D.J., and Whetsell W. Regional activities of metabolic enzymes and glutamate decarboxylase in human brain. Ann. Neurol. 10 (1981) 377-383
11. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 193 (2005) 279-290
12. Swerdlow R.H., Parks J.K., Cassarino D.S., Maguire D.J., Maguire R.S., Bennett Jr. J.P., Davis R.E., and Parker Jr. W.D. Cybrids in Alzheimer's disease: a cellular model of the disease?. Neurology 49 (1997) 918-925
13. Binder D.R., Dunn Jr. W.H., and Swerdlow R.H. Molecular characterization of mtDNA depleted and repleted NT2 cell lines. Mitochondrion 5 (2005) 255-265
14. Ragan C.I., Wilson M.T., Darley-Usmar V.M., and Lowe P.N. Subfractionation of mitochondria, and isolation of the proteins of oxidative phosphorylationdrial DNA depleted cells. Mitochondria, a practical approach (1987), IRL Press, London 79-112
15. Stocchi V., Cucchiarini L., Magnani M., Chiarantini L., Palma P., and Crescentini G. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Anal. Biochem. 146 (1985) 118-124
16. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
17. Martin-Clemente B., varez-Castelao B., Mayo I., Sierra A.B., Diaz V., Milan M., Farinas I., Gomez-Isla T., Ferrer I., and Castano J.G. Alpha-synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. J. Biol. Chem. 279 (2004) 52984-52990
18. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., and Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186 (1990) 464-478
19. Cardoso S.M., and Oliveira C.R. Inhibition of NF-kB renders cells more vulnerable to apoptosis induced by amyloid beta peptides. Free Radic. Res. 37 (2003) 967-973
20. Dawson T.M., and Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. 5 (2002) 1058-1061
21. Nagatsu T., and Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell. Mol. Neurobiol. 26 (2006) 781-802
22. Domingues A., Esteves A.R., Swerdlow R.H., Oliveira C.R., and Cardoso S.M. Calpain-mediated MPP(+) toxicity in mitochondrial DNA depleted cells. Neurotox. Res. J. 13 (2008) 31-38
23. Chung K.K., Dawson V.L., and Dawson T.M. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24 (2001) S7-14
24. McNaught K.S., and Olanow C.W. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S73-S84
25. Tanaka K. The ubiquitin-proteasome system and neurodegenerative disease. No To Shinkei 53 (2001) 935-942
26. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., and Greene L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21 (2001) 9549-9560
27. Chen L., Thiruchelvam M.J., Madura K., and Richfield E.K. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol. Dis. 23 (2006) 120-126
28. Ii K., Ito H., Tanaka K., and Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56 (1997) 125-131
29. Gai W.P., Yuan H.X., Li X.Q., Power J.T., Blumbergs P.C., and Jensen P.H. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 166 (2000) 324-333
30. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., and Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
31. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179 (2003) 38-46
32. Rossetti Z.L., Sotgiu A., Sharp D.E., Hadjiconstantinou M., and Neff N.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37 (1988) 4573-4574
33. Di M.D., Sandy M.S., Ekstrom G., and Smith M.T. Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochem. Biophys. Res. Commun. 137 (1986) 303-309
34. Testa C.M., Sherer T.B., and Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 134 (2005) 109-118
35. Tretter L., Sipos I., and dam-Vizi V. Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem. Res. 29 (2004) 569-577
36. Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., and Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl. Acad. Sci. USA 102 (2005) 19126-19131
37. Reinheckel T., Ullrich O., Sitte N., and Grune T. Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch. Biochem. Biophys. 377 (2000) 65-68
38. Bulteau A.L., Lundberg K.C., Humphries K.M., Sadek H.A., Szweda P.A., Friguet B., and Szweda L.I. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276 (2001) 30057-30063